NPS MedicineWise has published
a new edition of RADAR, including
a review of glycopyrronium (Seebri
Breezhaler), a new medicine for the
treatment of chronic obstructive
pulmonary disease (COPD).
The publication provides
information for health professionals
to put the new once-daily
long-acting anticholinergic
bronchodilator into clinical context.
It also details four new fixeddose
combination therapies of
metformin and gliptin listed on
the PBS for patients with type
2 diabetes: metformin with
alogliptin (Nesina Met); metformin
XR with saxagliptin (Kombiglyze
XR); linagliptin with metformin
(Trajentamet) and metformin XR;
and sitagliptin (Janument XR).
All four products are listed as
Authority Required (streamlined)
under specific conditions.
CLICK HERE to access RADAR.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Apr 14
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.